TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
JOINN Laboratories (China) Co., Ltd. Class H ( (HK:6127) ) has issued an announcement.
JOINN Laboratories has entered into two significant agreements: the 2026 Staidson Research and Development Service Framework Agreement and the 2026 BioAI Service Framework Agreement. These agreements, effective from January 1, 2026, to December 31, 2026, involve continuing connected transactions with Staidson and BioAI, both associated with the company’s controlling shareholders. The transactions are subject to reporting and annual review requirements under the Listing Rules, indicating a strategic move to strengthen its service offerings and maintain compliance with regulatory standards.
The most recent analyst rating on (HK:6127) stock is a Hold with a HK$16.30 price target. To see the full list of analyst forecasts on JOINN Laboratories (China) Co., Ltd. Class H stock, see the HK:6127 Stock Forecast page.
More about JOINN Laboratories (China) Co., Ltd. Class H
JOINN Laboratories (China) Co., Ltd. operates in the pharmaceutical industry, providing a comprehensive range of research and development services, including non-clinical and clinical trial stages, to various clients.
Average Trading Volume: 5,004,863
Technical Sentiment Signal: Sell
Current Market Cap: HK$21.25B
For an in-depth examination of 6127 stock, go to TipRanks’ Overview page.